Illuminox™ is a proprietary, anti-cancer treatment platform that is comprised of drug, device and other related technologies. Transient excitation of the drug, including monoclonal antibodies conjugated to proprietary light-excitable dyes, with non-thermal light is believed to result in anti-cancer activity, which is mediated by biophysical processes that may compromise the membrane integrity of cells. The requirement of targeted binding of the drug to a specific antigen on the cell surface, and subsequent illumination, is believed to result in rapid and selective cell killing and tumor necrosis with minimal effects on surrounding normal tissue. Rakuten Medical is currently studying the potential for therapies based on the Illuminox platform to induce innate and adaptive immunity. Illuminox is based upon the photoimmunotherapy treatment platform developed at the National Institutes of Health (NIH) and licensed exclusively to Rakuten Medical for commercialization.
Illuminox is the platform used for the development of specific therapies using a combination of drug, device and other technologies. No therapies using the Illuminox platform have been approved by any regulatory authority. The Illuminox platform is not a drug nor device available in clinical trials or by prescription. The Illuminox name is not the brand name of a drug nor device.